Magic mushroom compound shows promise for Hard-to-Treat depression and suicidal thoughts
NCT ID NCT05220410
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested a single 25mg dose of psilocybin in 20 adults with depression that didn't respond to standard treatments and who also had ongoing suicidal thoughts. The goal was to see if the drug is safe and tolerable in this high-risk group. Participants received the dose in a supportive setting, and researchers measured changes in suicidal thinking and depression severity.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SUICIDAL IDEATION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Sheppard Pratt Health System
Baltimore, Maryland, 21204, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can peer mentors help gay men with HIV stay in care?
- Brain 'Radio' tunes into Depression's neural signals
- Hope in action: peer support may curb suicide risk in youth facing psychosis
- Magic mushroom compound tested for dual relief of chronic pain and depression
- A phone call after the ER: testing a suicide prevention lifeline
- Can money worries trigger depression in students? a study digs deep